Pfizer Submits Favorable Initial Data To The FDA On Kids' COVID-19 Vaccine Trial
Pfizer and BioNTech are another step closer to seeking authorization for young children to receive the COVID-19 coronavirus vaccine, submitting data to the Food and Drug Administration that shows a 'robust' antibody response and 'favorable' safety outcomes in kids ages 5 to 11 who received the two-dose regimen in clinical trials. The companies plan to submit a formal request for emergency-use authorization of the vaccine for that age range 'in the coming weeks,' they said Tuesday. News of the data submission comes a week after Pfizer announced promising results from the trials, which have been closely watched by parents eager to protect their children from the coronavirus. COVID-19 has now killed more than 690,000 people in the U.S., with millions more sickened by the disease.
NPR - September 28, 2021View the full story here: https://www.npr.org/sections/coronavirus-live-updates/2021/09/28/1041100773/pfizer-fda-kids-covid-coronavirus-vaccine-authorization-results